QGEN vs TECH
QGEN: QIAGEN supplies essential molecular diagnostic and sample preparation tools that enable laboratories and clinicians to detect, analyze, and validate genetic material and biomarkers. TECH: A leading life sciences company providing essential reagents, analytical tools, and bio-manufacturing solutions for research and clinical diagnostics.
Side-by-side fundamentals
| Metric | QGEN | TECH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $40.57 | $71.78 | |
| Market cap as of 2026-07-23 | $8.4B | $11.2B | |
| P/E as of 2026-07-23 | 20.77 | 103.32 | QGEN lower |
| PEG as of 2026-07-23 | 3.13 | 11.45 | QGEN lower |
| Net margin as of 2026-07-23 | +19.2% | +9.0% | QGEN higher |
| Gross margin as of 2026-07-23 | +62.6% | +66.4% | TECH higher |
| Operating margin as of 2026-07-23 | +20.7% | +12.7% | QGEN higher |
| ROE as of 2026-07-23 | +11.3% | +5.4% | QGEN higher |
| ROA as of 2026-07-23 | +6.6% | +4.3% | QGEN higher |
| Debt / equity as of 2026-07-23 | 0.49 | 0.10 | TECH lower |
| Revenue growth (YoY) as of 2026-07-23 | +4.8% | +0.2% | QGEN higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +3.3% | |
| Dividend yield as of 2026-07-23 | +0.6% | +0.4% | QGEN higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.63 | 1.28 | |
| 1-year return as of 2026-07-22 close | -18.1% | +35.1% | TECH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.